ChemoCentryx, Inc. (CCXI): Price and Financial Metrics


ChemoCentryx, Inc. (CCXI): $51.99

0.03 (+0.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCXI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $51.99 52-week high $52.00
Prev. close $51.96 52-week low $14.95
Day low $51.98 Volume 2,480,300
Day high $52.00 Avg. volume 1,681,906
50-day MA $51.46 Dividend yield N/A
200-day MA $31.96 Market Cap 3.71B

ChemoCentryx, Inc. (CCXI) Company Bio


ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.


CCXI Latest News Stream


Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream


Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about CHEMOCENTRYX INC that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx shareholders approve $4.7B merger with Amgen

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephro

Yahoo | October 17, 2022

Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Yahoo | October 6, 2022

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meet

Yahoo | October 5, 2022

Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2022

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo N/A
3-mo N/A
6-mo 2.36%
1-year 87.08%
3-year 8.78%
5-year 458.43%
YTD N/A
2022 0.00%
2021 -41.20%
2020 56.56%
2019 262.51%
2018 83.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9135 seconds.